Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalGlobeNewsWire • 11/10/23
Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific MeetingGlobeNewsWire • 11/07/23
Pharming Group reports on results of the 2023 Extraordinary General Meeting of ShareholdersGlobeNewsWire • 09/25/23
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/22/23
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanPRNewsWire • 08/09/23
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardPRNewsWire • 07/18/23
Pharming Group to report second quarter and first half 2023 financial results on August 3PRNewsWire • 07/13/23
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?Zacks Investment Research • 04/21/23
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.PRNewsWire • 04/11/23
Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease DaysPRNewsWire • 03/30/23
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDSPRNewsWire • 03/24/23